Live vaccines—a short‐cut to cancer viro‐immunotherapy
Abstract Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint modifiers are urgently needed. In this issue of EMBO Molecular M...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2019-11-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201911496 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849343086463811584 |
|---|---|
| author | Thomas C Wirth Julia Niemann Florian Kühnel |
| author_facet | Thomas C Wirth Julia Niemann Florian Kühnel |
| author_sort | Thomas C Wirth |
| collection | DOAJ |
| description | Abstract Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint modifiers are urgently needed. In this issue of EMBO Molecular Medicine, Aznar et al present the already approved yellow fever vaccine 17D as an oncolytic agent for tumour immunoactivation. In tumour‐bearing mice, they demonstrated a convincing synergy of the vaccine with CD137 agonistic antibodies resulting in significantly improved survival. |
| format | Article |
| id | doaj-art-affb6d67f5ca4f5fa188d3709c0b00cc |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2019-11-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-affb6d67f5ca4f5fa188d3709c0b00cc2025-08-20T03:43:10ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842019-11-011211210.15252/emmm.201911496Live vaccines—a short‐cut to cancer viro‐immunotherapyThomas C Wirth0Julia Niemann1Florian Kühnel2Deparment of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical SchoolDeparment of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical SchoolDeparment of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical SchoolAbstract Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint modifiers are urgently needed. In this issue of EMBO Molecular Medicine, Aznar et al present the already approved yellow fever vaccine 17D as an oncolytic agent for tumour immunoactivation. In tumour‐bearing mice, they demonstrated a convincing synergy of the vaccine with CD137 agonistic antibodies resulting in significantly improved survival.https://doi.org/10.15252/emmm.201911496 |
| spellingShingle | Thomas C Wirth Julia Niemann Florian Kühnel Live vaccines—a short‐cut to cancer viro‐immunotherapy EMBO Molecular Medicine |
| title | Live vaccines—a short‐cut to cancer viro‐immunotherapy |
| title_full | Live vaccines—a short‐cut to cancer viro‐immunotherapy |
| title_fullStr | Live vaccines—a short‐cut to cancer viro‐immunotherapy |
| title_full_unstemmed | Live vaccines—a short‐cut to cancer viro‐immunotherapy |
| title_short | Live vaccines—a short‐cut to cancer viro‐immunotherapy |
| title_sort | live vaccines a short cut to cancer viro immunotherapy |
| url | https://doi.org/10.15252/emmm.201911496 |
| work_keys_str_mv | AT thomascwirth livevaccinesashortcuttocancerviroimmunotherapy AT julianiemann livevaccinesashortcuttocancerviroimmunotherapy AT floriankuhnel livevaccinesashortcuttocancerviroimmunotherapy |